The relationship between cumulative dose of immunosuppressive agents and COVID-19-associated mucormycosis: A multicenter cross-sectional study.
Mohsen RastkarSeyedAhmad SeyedAlinaghiBehzad AsanjaraniGoli SiriHamed AbdollahiLadan GhadamiMehrdad HasibiRozita KhodashahiAmirBehzad BagheriAli Asadollahi-AminPublished in: Health science reports (2022)
The prevalence of COVID-19-associated mucormycosis is increasing and should be considered in the treatment protocols of COVID-19. Controlling risk factors such as diabetes, malignancy and the administration of immunosuppressive agents based on recommended dosage in validated guidelines are ways to prevent mucormycosis.